Clinical Trials
11 trialsNCT03994796 2026-04-13
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT05853575 2026-03-27
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Mirati Therapeutics Inc.
Phase 2 Active not recruiting
NCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT05162443 2025-08-26
Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation
Bristol-Myers Squibb
Approved for marketing
NCT04418661 2025-05-29
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
Sanofi
Phase 1/2 Terminated
NCT05375994 2025-05-18
RAMP204
Verastem, Inc.
Phase 1/2 Active not recruiting
NCT05840510 2025-04-25
Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT04330664 2025-04-04
Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)
Mirati Therapeutics Inc.
Phase 1 Completed
NCT04685135 2025-01-22
KRYSTAL-12
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT04975256 2024-12-16
Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT05263986 2023-02-27
The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1 Unknown